28-Feb-2008 - MorphoSys AG

Sigma-Aldrich and MorphoSys Enter Into a Collaboration and Licensing Agreement for Recombinant Research Antibodies

AbD Serotec will use proprietary technology to generate antibodies against novel research targets provided by Sigma-Aldrich

Sigma-Aldrich and MorphoSys AG announced a collaboration agreement to design, produce and distribute unique recombinant research antibodies using MorphoSys's proprietary HuCAL GOLD(R) technology. MorphoSys's AbD Serotec unit will develop and qualify unique antibodies from MorphoSys's proprietary HuCAL GOLD library against a committed number of targets identified and supplied by Sigma-Aldrich.

"We are very excited about the potential of this partnership," said Dr. David Smoller, president of Sigma-Aldrich's Research Biotech business unit. "HuCAL-based recombinant antibody technology will allow researchers access to antibody content not available through standard antibody generation technologies. In conjunction with Sigma-Aldrich's standard content generation capabilities, this powerful technology is expected to allow the community to reach its goal of a binder for every gene and one-day even protein in the human body."

Facts, background information, dossiers
  • antibodies
  • Sigma-Aldrich
  • MorphoSys
  • AbD Serotec
  • Binder
More about MorphoSys
  • News

    MorphoSys Unveils New Antibody Library

    MorphoSys AG (Neuer Markt: MOR) today announced the development and release of a new proprietary antibody library, HuCAL® GOLD. The library is to be presented at the 12th IBC Antibody Engineering conference in San Diego, California. Initial results show that the new library and related scre ... more

    MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration

    MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today an Agreement with Oridis Biomed Forschungs- und Entwicklungs GmbH, Graz, Austria, that will provide MorphoSys with preferred access to one of the world’s largest human tissue banks. The goal of the collaborat ... more

    MorphoSys Expands Target Discovery Capability in Oridis Biomed Collaboration

    MorphoSys AG (Neuer Markt: MOR), the German biotechnology company, announced today that a court in San Diego has granted its motion to dismiss a second attempt by Cambridge Antibody Technology Ltd. (CAT), together with The Medical Research Council, The Scripps Research Institute and Stratag ... more

  • Job Offers

    Medical Director / Medical Scientist (gn) in Clinical Development

    We would like to fill the following vacancy as soon as possible: Provide medical expertise to clinical programs for tafasitamab – in the area of oncology. Focus on design, timely preparation and execution of the clinical trial(s) Prepare or oversee preparation of clinical trial protoco ... more

    Clinical Trial Manager (gn)

    We would like to fill the following vacancy as soon as possible: Contributes to planning of global clinical trials and designs site management processes from study start-up to closure in collaboration with global CRO(s) and sponsor Clinical Trial Team (CTT) meeting the requirements of the ... more

    Scientist Clinical Biomarkers (gn)

    We would like to fill the following vacancy as soon as possible: Develop and implement clinical biomarker strategies in collaboration with clinical department Identify Contract Research Organizations (CROs) for outsourced biomarker testing in the context of clinical trials Manage C ... more

More about Sigma-Aldrich